Summit Therapeutics Inc (SMMT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$17.61+2.80%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SMMT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -33.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers
SMMT — earnings miss
Dated 2026-07-23
and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Why it matters: Managing cash flow is key for ongoing operations. High cash burn could worry about financial health.
Worry ifOperating cash flow shows improvement or a smaller net loss.
Less concerning ifOperating cash flow gets worse or net losses rise a lot.
Why it matters: Finishing enrollment will lead to important data releases. This could prove ivonescimab works in NSCLC.
Supportive ifEnrollment in the HARMONi-3 study is done, leading to new data releases.
Worry ifEnrollment is not complete yet. This delays data analysis.
Why it matters: Cash burn trends will indicate financial health as clinical trials expand. It's crucial for sustainability.
Worry ifOperating cash burn goes down compared to previous quarters.
Less concerning ifOperating cash burn goes up a lot compared to previous quarters.
Why it matters: The FDA's decision on the BLA will affect ivonescimab's market in NSCLC. A good decision could create big money opportunities.
Supportive ifFDA approves the BLA for ivonescimab by the PDUFA date of November 14, 2026.
Worry ifFDA rejects the BLA for ivonescimab or delays the decision beyond the PDUFA date.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$238 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $680 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,288 loss on $10,000 · 52.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Completing enrollment is a key step in advancing the study of ivonescimab in NSCLC. This could lead to faster data readouts.
Supportive ifEnrollment in HARMONi-7 is confirmed complete by the end of 2026.
Worry ifEnrollment in HARMONi-7 is not completed by the end of 2026.